[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591973":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":30,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":88,"whyStopped":30,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vibegron","EXPERIMENTAL","Participants in this arm will take 75mg\u002Fday Vibegron for 12 weeks.",[13],"Drug: Vibegron",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants in this arm will take placebo daily for 12 weeks.",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","A drug in a class of medications called beta-3 adrenergic agonists; approved for use with Overactive Bladder; 75mg tablets will be used in this study",[9],[26],"Gemtesa",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Tablets made of inert substance that looks like the vibegron tablets but has no therapeutic value",[15],null,[32],{"name":33,"affiliation":5,"role":34},"Tina E Brinkley, PhD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Tina E. Brinkley, PhD","CONTACT","336-713-8534","tbrinkle@wakehealth.edu",[42],{"facility":5,"status":30,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Winston-Salem","North Carolina","27157","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-80.24422,36.09986,{"lat":52,"lon":51},[55,56],{"name":33,"role":38,"phone":39,"phoneExt":30,"email":30},{"name":33,"role":34,"phone":30,"phoneExt":30,"email":30},{"type":58,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[60],{"name":61,"class":62},"National Institute on Aging (NIA)","NIH","100591973","phase-3-vibegron-for-energy-thinking-and-resilience-in-aging-100591973",false,"NCT06987383","Vibegron for ENergy Thinking and Resilience in Aging","Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity","VENTURA","Inclusion Criteria:\n\n* Obese (BMI ≥30 kg\u002Fm2 or BMI ≥27 kg\u002Fm2 with a waist circumference \\>102 cm for men and \\>88 cm for women)\n\nExclusion Criteria:\n\n* Body weight ≥450 pounds\n* Major depression\n* Evidence of cognitive impairment\n* Uncontrolled diabetes (hemoglobin A1c \\>7%)\n* Weight gain or loss of ≥5% over the past 6 months\n* Prior weight loss procedure (e.g., gastric bypass, sleeve gastrectomy, gastric banding)\n* Regular use of the following: weight loss medications (e.g., Orlistat, Belviq, Contrave, Saxenda, Phentermine, Qsymia); medications or dietary supplements known to alter energy metabolism; adrenergic agonists or beta blockers\n* Symptoms of urinary retention, incontinence, urgency, and frequency or current use of an antimuscarinic medication to treat overactive bladder\n* Benign prostate hyperplasia\n* Significant medical illness or organ failure, such as uncontrolled hypertension, advanced kidney disease, liver disease, thyroid disease, or active neoplastic disease\n* Diagnosis of a neurodegenerative illness (e.g., mild cognitive impairment, dementia, Parkinson's disease, Multiple Sclerosis)\n* History of a clinically significant stroke\n* Cardiac arrhythmia or an abnormal Electrocardiogram\n* Drug\u002Fsubstance abuse or excessive alcohol use within the past 6 months\n* Contraindication to Vibegron or any of its components\n* Current participation in another intervention or research study that prohibits co-enrollment","ALL","45 Years","75 Years",{"count":75,"type":76},40,"ESTIMATED","INTERVENTIONAL",[79],"PHASE3","This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.",[82],"Obesity",[9,84,85,86,87],"aging","metabolism","physical function","cognitive function","NOT_YET_RECRUITING","2026-08-03",{"date":91,"type":92},"2026-08-04","ACTUAL",{"date":94,"type":76},"2026-09",{"date":96,"type":76},"2028-07",{"name":5,"class":6},1]